ANTHONY C HOOPER Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for ANTHONY C HOOPER.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of ANTHONY C HOOPER. ANTHONY C HOOPER is EVP, Global Commercial Ops. in AMGEN INC ($AMGN) and President US Pharmaceuticals in BRISTOL MYERS SQUIBB CO ($BMY) and Director in MANNKIND CORP ($MNKD) and Director in BeiGene, Ltd. ($BGNE).
Latest Insider Trading Transactions of ANTHONY C HOOPER
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, AMGN, BGNE, BMY, MNKD
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 19 2020 | BGNE | BeiGene, Ltd. | HOOPER ANTHONY C | Director | Option Exercise | A | 13.42 | 45,383 | 609,040 | 45,383 | |
| May 26 2020 | MNKD | MANNKIND CORP | HOOPER ANTHONY C | Director | Option Exercise | A | 0.00 | 38,760 | 0 | 38,760 | |
| May 26 2020 | MNKD | MANNKIND CORP | HOOPER ANTHONY C | Director | Option Exercise | A | 0.00 | 88,235 | 0 | 88,235 | |
| Mar 06 2020 | BGNE | BeiGene, Ltd. | HOOPER ANTHONY C | Director | Option Exercise | A | 12.22 | 21,970 | 268,473 | 21,970 | |
| Mar 04 2020 | MNKD | MANNKIND CORP | HOOPER ANTHONY C | Director | Grant | A | 0.00 | 30,048 | 0 | 126,201 | 96.2 K to 126.2 K (+31.25 %) |
| May 07 2018 | AMGN | AMGEN INC | HOOPER ANTHONY C | EVP, Global Commerc ... | Payment of Exercise | F | 169.43 | 883 | 149,607 | 215,147 | 216 K to 215.1 K (-0.41 %) |
| May 01 2018 | AMGN | AMGEN INC | HOOPER ANTHONY C | EVP, Global Commerc ... | Option Exercise | A | 177.46 | 34,702 | 6,158,217 | 34,702 | |
| May 01 2018 | AMGN | AMGEN INC | HOOPER ANTHONY C | EVP, Global Commerc ... | Grant | A | 0.00 | 4,508 | 0 | 216,030 | 211.5 K to 216 K (+2.13 %) |
| Mar 27 2018 | AMGN | AMGEN INC | HOOPER ANTHONY C | EVP, Global Commerc ... | Payment of Exercise | F | 176.08 | 8,807 | 1,550,737 | 211,522 | 220.3 K to 211.5 K (-4.00 %) |
| Mar 09 2018 | AMGN | AMGEN INC | HOOPER ANTHONY C | EVP, Global Commerc ... | Grant | A | 0.00 | 17,638 | 0 | 220,121 | 202.5 K to 220.1 K (+8.71 %) |
| Feb 01 2018 | AMGN | AMGEN INC | HOOPER ANTHONY C | EVP, Global Commerc ... | Payment of Exercise | F | 191.27 | 651 | 124,517 | 202,483 | 203.1 K to 202.5 K (-0.32 %) |
| Feb 01 2018 | AMGN | AMGEN INC | HOOPER ANTHONY C | EVP, Global Commerc ... | Payment of Exercise | F | 198.00 | 575 | 113,850 | 203,134 | 203.7 K to 203.1 K (-0.28 %) |
| May 03 2017 | AMGN | AMGEN INC | HOOPER ANTHONY C | EVP, Global Commerc ... | Option Exercise | A | 162.60 | 43,572 | 7,084,807 | 43,572 | |
| May 03 2017 | AMGN | AMGEN INC | HOOPER ANTHONY C | EVP, Global Commerc ... | Grant | A | 0.00 | 4,920 | 0 | 203,402 | 198.5 K to 203.4 K (+2.48 %) |
| Mar 28 2017 | AMGN | AMGEN INC | HOOPER ANTHONY C | EVP, Global Commerc ... | Payment of Exercise | F | 166.04 | 12,128 | 2,013,733 | 198,482 | 210.6 K to 198.5 K (-5.76 %) |
| Mar 09 2017 | AMGN | AMGEN INC | HOOPER ANTHONY C | EVP, Global Commerc ... | Grant | A | 0.00 | 23,092 | 0 | 210,397 | 187.3 K to 210.4 K (+12.33 %) |
| Feb 02 2017 | AMGN | AMGEN INC | HOOPER ANTHONY C | EVP, Global Commerc ... | Payment of Exercise | F | 154.43 | 668 | 103,159 | 187,305 | 188 K to 187.3 K (-0.36 %) |
| Jan 31 2017 | AMGN | AMGEN INC | HOOPER ANTHONY C | EVP, Global Commerc ... | Payment of Exercise | F | 157.16 | 598 | 93,982 | 187,973 | 188.6 K to 188 K (-0.32 %) |
| Jan 31 2017 | AMGN | AMGEN INC | HOOPER ANTHONY C | EVP, Global Commerc ... | Payment of Exercise | F | 157.16 | 1,053 | 165,489 | 188,571 | 189.6 K to 188.6 K (-0.56 %) |
| May 05 2016 | AMGN | AMGEN INC | HOOPER ANTHONY C | EVP, Global Commerc ... | Option Exercise | A | 156.35 | 43,557 | 6,810,137 | 43,557 | |
| May 05 2016 | AMGN | AMGEN INC | HOOPER ANTHONY C | EVP, Global Commerc ... | Grant | A | 0.00 | 5,116 | 0 | 189,312 | 184.2 K to 189.3 K (+2.78 %) |
| Apr 29 2016 | AMGN | AMGEN INC | HOOPER ANTHONY C | EVP, Global Commerc ... | Payment of Exercise | F | 162.85 | 1,659 | 270,168 | 184,196 | 185.9 K to 184.2 K (-0.89 %) |
| Mar 29 2016 | AMGN | AMGEN INC | HOOPER ANTHONY C | EVP, Global Commerc ... | Payment of Exercise | F | 149.24 | 23,785 | 3,549,673 | 185,855 | 209.6 K to 185.9 K (-11.35 %) |
| Mar 04 2016 | AMGN | AMGEN INC | HOOPER ANTHONY C | EVP, Global Commerc ... | Grant | A | 0.00 | 45,268 | 0 | 209,230 | 164 K to 209.2 K (+27.61 %) |
| Feb 01 2016 | AMGN | AMGEN INC | HOOPER ANTHONY C | EVP, Global Commerc ... | Payment of Exercise | F | 152.73 | 651 | 99,427 | 163,962 | 164.6 K to 164 K (-0.40 %) |
| Feb 01 2016 | AMGN | AMGEN INC | HOOPER ANTHONY C | EVP, Global Commerc ... | Payment of Exercise | F | 150.47 | 995 | 149,718 | 164,339 | 165.3 K to 164.3 K (-0.60 %) |
| Apr 28 2015 | AMGN | AMGEN INC | HOOPER ANTHONY C | EVP, Global Commerc ... | Payment of Exercise | F | 167.91 | 1,575 | 264,458 | 165,334 | 166.9 K to 165.3 K (-0.94 %) |
| Mar 31 2015 | AMGN | AMGEN INC | HOOPER ANTHONY C | EVP, Global Commerc ... | Payment of Exercise | F | 160.55 | 28,624 | 4,595,583 | 166,909 | 195.5 K to 166.9 K (-14.64 %) |
| Mar 13 2015 | AMGN | AMGEN INC | HOOPER ANTHONY C | EVP, Global Commerc ... | Payment of Exercise | F | 153.58 | 27,540 | 4,229,593 | 195,148 | 222.7 K to 195.1 K (-12.37 %) |
| Mar 06 2015 | AMGN | AMGEN INC | HOOPER ANTHONY C | EVP, Global Commerc ... | Grant | A | 0.00 | 107,354 | 0 | 222,688 | 115.3 K to 222.7 K (+93.08 %) |
| Mar 03 2015 | AMGN | AMGEN INC | HOOPER ANTHONY C | EVP, Global Commerc ... | Payment of Exercise | F | 157.72 | 3,215 | 507,070 | 115,334 | 118.5 K to 115.3 K (-2.71 %) |
| Mar 06 2008 | BMY | BRISTOL MYERS SQUI ... | HOOPER ANTHONY C | President US Pharma ... | Option Exercise | A | 0.00 | 13,077 | 0 | 13,077 | |
| Mar 06 2008 | BMY | BRISTOL MYERS SQUI ... | HOOPER ANTHONY C | President US Pharma ... | Option Exercise | A | 22.14 | 171,495 | 3,796,899 | 171,495 | |
| Mar 04 2008 | BMY | BRISTOL MYERS SQUI ... | HOOPER ANTHONY C | President US Pharma ... | Payment of Exercise | F | 22.61 | 1,178 | 26,635 | 102,331 | 103.5 K to 102.3 K (-1.14 %) |
| Mar 04 2008 | BMY | BRISTOL MYERS SQUI ... | HOOPER ANTHONY C | President US Pharma ... | Payment of Exercise | F | 22.61 | 1,038 | 23,469 | 103,509 | 104.5 K to 103.5 K (-0.99 %) |
| Sep 12 2007 | BMY | BRISTOL MYERS SQUI ... | HOOPER ANTHONY C | President US Pharma ... | Payment of Exercise | F | 0.00 | 3,871 | 0 | 104,558 | 108.4 K to 104.6 K (-3.57 %) |
| Jun 21 2007 | BMY | BRISTOL MYERS SQUI ... | HOOPER ANTHONY C | President US Pharma ... | Payment of Exercise | F | 31.23 | 2,431 | 75,920 | 95,549 | 98 K to 95.5 K (-2.48 %) |
| Jun 01 2007 | BMY | BRISTOL MYERS SQUI ... | HOOPER ANTHONY C | President US Pharma ... | Option Exercise | M | 28.90 | 30,000 | 867,000 | 0 | |
| Jun 01 2007 | BMY | BRISTOL MYERS SQUI ... | HOOPER ANTHONY C | President US Pharma ... | Payment of Exercise | F | 30.12 | 443 | 13,343 | 97,980 | 98.4 K to 98 K (-0.45 %) |
| Jun 01 2007 | BMY | BRISTOL MYERS SQUI ... | HOOPER ANTHONY C | President US Pharma ... | Payment of Exercise | F | 30.12 | 28,785 | 867,004 | 98,423 | 127.2 K to 98.4 K (-22.63 %) |
| Jun 01 2007 | BMY | BRISTOL MYERS SQUI ... | HOOPER ANTHONY C | President US Pharma ... | Buy | M | 28.90 | 30,000 | 867,000 | 127,208 | 97.2 K to 127.2 K (+30.86 %) |
| Jun 22 2006 | BMY | BRISTOL MYERS SQUI ... | HOOPER ANTHONY C | President US Pharma ... | Payment of Exercise | F | 25.48 | 2,431 | 61,942 | 113,165 | 115.6 K to 113.2 K (-2.10 %) |
| Mar 09 2006 | BMY | BRISTOL MYERS SQUI ... | HOOPER ANTHONY C | President US Pharma ... | Option Exercise | A | 22.73 | 78,750 | 1,789,988 | 78,750 | |
| Mar 09 2006 | BMY | BRISTOL MYERS SQUI ... | HOOPER ANTHONY C | President US Pharma ... | Payment of Exercise | F | 22.73 | 1,862 | 42,323 | 115,596 | 117.5 K to 115.6 K (-1.59 %) |
| Mar 09 2006 | BMY | BRISTOL MYERS SQUI ... | HOOPER ANTHONY C | President US Pharma ... | Grant | A | 22.73 | 5,107 | 116,082 | 117,458 | 112.4 K to 117.5 K (+4.55 %) |
| Mar 09 2006 | BMY | BRISTOL MYERS SQUI ... | HOOPER ANTHONY C | President US Pharma ... | Grant | A | 22.73 | 18,900 | 429,597 | 112,351 | 93.5 K to 112.4 K (+20.22 %) |
| Jul 12 2005 | BMY | BRISTOL MYERS SQUI ... | HOOPER ANTHONY C | President US Pharma ... | Payment of Exercise | F | 24.82 | 639 | 15,860 | 68,451 | 69.1 K to 68.5 K (-0.92 %) |
| Sep 21 2005 | BMY | BRISTOL MYERS SQUI ... | HOOPER ANTHONY C | President US Pharma ... | Grant | A | 0.00 | 25,000 | 0 | 93,451 | 68.5 K to 93.5 K (+36.52 %) |
| Jun 22 2005 | BMY | BRISTOL MYERS SQUI ... | HOOPER ANTHONY C | President US Pharma ... | Payment of Exercise | F | 0.00 | 2,430 | 0 | 69,090 | 71.5 K to 69.1 K (-3.40 %) |
| Mar 03 2005 | BMY | BRISTOL MYERS SQUI ... | HOOPER ANTHONY C | President US Pharma ... | Option Exercise | A | 25.45 | 55,833 | 1,420,950 | 55,833 | |
| Mar 03 2005 | BMY | BRISTOL MYERS SQUI ... | HOOPER ANTHONY C | President US Pharma ... | Grant | A | 0.00 | 9,306 | 0 | 71,520 | 62.2 K to 71.5 K (+14.96 %) |
| Jul 12 2004 | BMY | BRISTOL MYERS SQUI ... | HOOPER ANTHONY C | President US Pharma ... | Payment of Exercise | F | 24.19 | 587 | 14,200 | 62,214 | 62.8 K to 62.2 K (-0.93 %) |
| Mar 04 2004 | BMY | BRISTOL MYERS SQUI ... | HOOPER ANTHONY C | President US Pharma ... | Option Exercise | A | 28.11 | 63,333 | 1,780,291 | 63,333 | |
| Mar 04 2004 | BMY | BRISTOL MYERS SQUI ... | HOOPER ANTHONY C | President US Pharma ... | Grant | A | 0.00 | 10,556 | 0 | 62,801 | 52.2 K to 62.8 K (+20.20 %) |
Page: 1